[go: up one dir, main page]

WO2006126082A3 - Pyridine [3,4-b] pyrazinones - Google Patents

Pyridine [3,4-b] pyrazinones Download PDF

Info

Publication number
WO2006126082A3
WO2006126082A3 PCT/IB2006/001387 IB2006001387W WO2006126082A3 WO 2006126082 A3 WO2006126082 A3 WO 2006126082A3 IB 2006001387 W IB2006001387 W IB 2006001387W WO 2006126082 A3 WO2006126082 A3 WO 2006126082A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazinones
pde
pyridine
inhibitors
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001387
Other languages
English (en)
Other versions
WO2006126082A2 (fr
Inventor
Alan George Benson
Andrew Simon Bell
David Graham Brown
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Robert Owen Hughes
Eric Jon Jacobsen
Brent Virgil Mischke
John Major Molyneaux
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
Jr Donald Joseph Rogier
John Keith Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Priority to CA002608672A priority Critical patent/CA2608672A1/fr
Publication of WO2006126082A2 publication Critical patent/WO2006126082A2/fr
Publication of WO2006126082A3 publication Critical patent/WO2006126082A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne des composés, des tautomères de ces composés, et des sels pharmaceutiquement acceptables de ces composés ou tautomères. Ces composés possèdent une structure représentée par la formule (I), dans laquelle R2, X6, Y6, R6 et R8 sont définis dans les pièces descriptives de la demande. Des compositions pharmaceutiques correspondantes, des procédés de traitement, des procédés de synthèse et des intermédiaires sont également divulgués.
PCT/IB2006/001387 2005-05-24 2006-05-17 Pyridine [3,4-b] pyrazinones Ceased WO2006126082A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002608672A CA2608672A1 (fr) 2005-05-24 2006-05-17 Pyridine [3,4-b] pyrazinones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413905P 2005-05-24 2005-05-24
US60/684,139 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006126082A2 WO2006126082A2 (fr) 2006-11-30
WO2006126082A3 true WO2006126082A3 (fr) 2007-01-25

Family

ID=37056557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001387 Ceased WO2006126082A2 (fr) 2005-05-24 2006-05-17 Pyridine [3,4-b] pyrazinones

Country Status (2)

Country Link
CA (1) CA2608672A1 (fr)
WO (1) WO2006126082A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51885B (sr) * 2006-04-21 2012-02-29 Pfizer Products Inc. PIRIDIN[3,4-b] PIRAZINONI
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
PT2247292T (pt) 2008-03-05 2017-07-17 Merck Patent Gmbh Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
WO2013030713A1 (fr) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2893256A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
SG11201505878UA (en) 2013-02-19 2015-09-29 Pfizer Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
CA2944308A1 (fr) 2014-04-01 2015-10-08 Pfizer Inc. Chromene et 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones comme modulateurs de gamma-secretase
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
ES2733502T3 (es) 2014-08-06 2019-11-29 Pfizer Compuestos de imidazopiridazina
DK3253755T3 (da) 2015-02-03 2020-09-28 Pfizer Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
PL3310784T3 (pl) 2015-06-17 2021-03-08 Pfizer Inc. Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
WO2017051294A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-diméthyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides utiles comme inhibiteurs de bace
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
CN113332292A (zh) 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
DK3642202T3 (da) 2017-06-22 2023-01-30 Pfizer Dihydro-pyrrolo-pyridin-derivater
AR115015A1 (es) 2018-03-23 2020-11-18 Pfizer Derivados de azaespiro piperazina
EP4297868A4 (fr) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076954A1 (fr) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (fr) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
WO2004031189A1 (fr) * 2002-09-30 2004-04-15 Bristol-Myers Squibb Pharma Company Pyrazinones pyridino et pyrimidino destinees au traitement de l'anxiete et de la depression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (fr) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
WO2002076954A1 (fr) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
WO2004031189A1 (fr) * 2002-09-30 2004-04-15 Bristol-Myers Squibb Pharma Company Pyrazinones pyridino et pyrimidino destinees au traitement de l'anxiete et de la depression

Also Published As

Publication number Publication date
WO2006126082A2 (fr) 2006-11-30
CA2608672A1 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006126082A3 (fr) Pyridine [3,4-b] pyrazinones
WO2006126081A3 (fr) Pyridine [2,3-b] pyrazinones
MY148583A (en) Pyridine [3,4-b] pyrazinones
WO2006032342A3 (fr) Medicament contenant des composes carbonyles et leur utilisation
WO2006087543A8 (fr) Composés antibactériens dérivés de pipéridine
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
WO2009016560A3 (fr) Dérivés de trans-3-aza-bicyclo[3.1.0]hexane
WO2008121687A3 (fr) Composés imidazo[1,2-a]pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur
WO2004101528A3 (fr) Inhibiteurs de la gfat
WO2006124490A3 (fr) Heterocycles utilises comme agonistes du recepteur de l'acide nicotinique dans le traitement de la dyslipidemie
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2005103037A3 (fr) Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments
TW200716628A (en) Novel compounds
WO2009156951A3 (fr) Composés de 5,6,7,8-tétrahydro-imidazo[1,5-a]pyrazine
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
MX2007002324A (es) Derivados de pirrolo[2-3-c]piridina y procesos para la preparacion de los mismos.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2005080352A3 (fr) Derives de quinazoline et leur utilisation therapeutique
WO2006065590A3 (fr) Compositions antivirales a base de pyridines et de pyrimidines
WO2006000371A3 (fr) Derives de pyrimidine
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2008104473A3 (fr) Inhibiteurs de kinase et procédés d'utilisation de ces derniers
WO2005075450A3 (fr) Nouveaux composes spiro-pentacycliques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2608672

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744778

Country of ref document: EP

Kind code of ref document: A2